Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | DPP4 | P27487 | 2/20 | 0.42 |
| ▸ | ACACB | O00763 | 2/20 | 0.42 |
| ▸ | TPH1 | P17752 | 6/20 | 0.40 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.39 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 3/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.38 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4649536 | 0.99 | ALDH1A1 (0.51) | ALDH1A1DPP4ACACBTPH1GPR142 | |
| Hydrochloric Acid SCHEMBL4649540 | 0.99 | ALDH1A1 (0.51) | ALDH1A1DPP4ACACBTPH1GPR142 | |
| SCHEMBL4648020 | 0.91 | TPH1 (0.48) | ALDH1A1DPP4ACACBTPH1GPR142 | |
| SCHEMBL14586456 | 0.90 | DPP4 (0.44) | ALDH1A1DPP4ACACBTPH1GPR142 | |
| Hydrochloric Acid SCHEMBL4648024 | 0.90 | TPH1 (0.48) | ALDH1A1DPP4ACACBTPH1GPR142 | |
| Hydrochloric Acid SCHEMBL4648016 | 0.90 | TPH1 (0.48) | ALDH1A1DPP4ACACBTPH1GPR142 | |
| SCHEMBL919060 | 0.84 | ALDH1A1 (0.52) | ALDH1A1TPH1ITGB1ITGA4ITGB7 | |
| SCHEMBL539320 | 0.83 | DPP4 (0.53) | ALDH1A1DPP4TPH1GPR142NLRP3 | |
| SCHEMBL539319 | 0.83 | DPP4 (0.53) | ALDH1A1DPP4TPH1GPR142NLRP3 | |
| SCHEMBL539309 | 0.83 | DPP4 (0.53) | ALDH1A1DPP4TPH1GPR142NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1701933-B1 | NOVEL COMPOUNDS | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-09-03 | — | — | EP | disclosed |
| US-20070043113-A1 | Novel compounds | TANABE SEIYAKU CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1701933-A1 | NOVEL COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005061440-A1 | NOVEL COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043113-A1 | Novel compounds | VCAM1, ICAM1, EPCAM | ALDH1A1 2146/4885DPP4 62/4885ACACB 1569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.